Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.69 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11915953 | 0.83 | ALDH1A1 (0.73) | ALDH1A1LMNANPSR1POLBHTT | |
| SCHEMBL9932677 | 0.78 | ALDH1A1 (0.44) | ALDH1A1LMNAMEN1KMT2ATP53 | |
| SCHEMBL9963099 | 0.74 | ALDH1A1 (0.68) | ALDH1A1LMNANPSR1HTTMEN1 | |
| SCHEMBL22095315 | 0.74 | ALDH1A1 (0.63) | ALDH1A1LMNANPSR1POLBHTT | |
| SCHEMBL27326048 | 0.72 | ALDH1A1 (0.38) | ALDH1A1LMNANPSR1POLBHTT | |
| SCHEMBL15221306 | 0.71 | ALDH1A1 (0.38) | ALDH1A1LMNANPSR1MEN1KMT2A | |
| SCHEMBL11915931 | 0.71 | SIGMAR1 (0.39) | ALDH1A1LMNAMEN1KMT2ASIGMAR1 | |
| SCHEMBL22113452 | 0.70 | ALDH1A1 (0.81) | ALDH1A1LMNANPSR1HTTMEN1 | |
| SCHEMBL4416287 | 0.69 | ALDH1A1 (0.58) | ALDH1A1LMNANPSR1POLBHTT | |
| SCHEMBL22069560 | 0.67 | ALDH1A1 (0.51) | ALDH1A1LMNANPSR1SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912330-B2 | Azaindole derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20110294806-A1 | AZAINDOLE DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294806-A1 | AZAINDOLE DERIVATIVES AS KINASE INHIBITORS | ABL1, CDKN1A, MAP3K13 | ALDH1A1 2111/4885LMNA 4433/4885NPSR1 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.